An ongoing dialogue on HIV/AIDS, infectious diseases,
January 8th, 2012
Journal Club: In Early HIV Infection, Little Reason to Delay Therapy
Every experienced HIV clinician will recognize the following new-patient scenario:
- At least one, but often several negative HIV antibody tests in the past, generally due to being in a “high risk” group.
- Recent non-specific viral-type illness that, in hindsight, was undoubtedly acute HIV infection, undiagnosed.
- Now completely recovered, but found to be newly HIV antibody positive.
- Physical exam normal, CD4 500 or higher, HIV RNA in the moderate range (10-100K).
How should patients like these be managed? Specifically, should antiretroviral therapy be started, or should they be observed?
Over in Journal of Infectious Diseases, the so-called Setpoint study — a randomized strategy trial — investigated whether a 36-week period of treatment would delay the need to go on continuous HIV therapy, compared with observation. After 130 of a planned 150 patients were enrolled, a Data Safety Monitoring Board elected to stop the study due to this key finding: “… the higher rate of progression to needing treatment in the Deferred Treatment group (50%) versus the Immediate Treatment (10%) group.”
Importantly, the findings would have been even stronger in favor of Immediate Treatment if more up-to-date CD4 thresholds (500 rather than 350) were used as a criterion to start therapy. (The study was designed in the mid 2000s.)
How do these results influence practice? As I’ve noted before, patients diagnosed with recently-acquired HIV infection should be counseled that even if treatment is deferred, there is a high likelihood they will need to start treatment relatively soon.
It’s also time to retire the “you may have 10 years before needing to go on therapy” counseling, something we might have been prone to do in the past to soften the blow of someone hearing that they’re HIV positive. This kind of delay is highly unlikely, and may be limited to the small fraction of patients who have very low HIV RNA and very high CD4s.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Global Cholera-Control Efforts — Progress and Remaining Challenges June 6, 2026If the current cholera pandemic, which began in 1961, is ever to end, the world will need better cholera vaccines that are effective in young children and global access to safe water and adequate sanitation.
- Childhood Vaccine Hesitancy June 4, 2026Vaccine hesitancy is often driven by safety concerns. Clinician recommendations, presumptive communication, and empathy improve uptake; maintaining trust supports future acceptance and community protection.
- War and Famine June 4, 2026The prevalence of wasting among children in Gaza tracks with Israeli blockades on aid, but war may lead to famine even without such policies. How should starvation be prevented and treated in wartime?
- The Unusual Suspects June 4, 2026A 53-year-old man with Crohn’s disease and psoriasis presented with a 2-day history of headache, slurred speech, nausea, and vomiting. During the previous 2 weeks, he had had yellowing of the skin and eyes and dark urine.
- Sudan Virus Disease in Uganda, 2025 June 3, 2026In January 2025, an outbreak of disease caused by Sudan virus, an ebolavirus, was identified in Uganda. Characteristics of this outbreak are described.
- Global Cholera-Control Efforts — Progress and Remaining Challenges June 6, 2026